Belantamab mafodotin in RRMM: Latest updates and practical considerations
The Multiple Myeloma Hub spoke with Christoph Renner, University of Basel, Basel, CH. We asked about the use of belantamab mafodotin-based combination therapy for relapsed/refractory multiple myeloma (RRMM). During this interview, Renner provides an overview of pivotal clinical data from the DREAMM-7 and DREAMM-8 trials that supported regulatory approvals of belantamab mafodotin-based combinations in RRMM and outlines practical considerations for their use in clinical practice. Renner discusses patient selection and treatment sequencing alongside other BCMA-directed therapies, as well as the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.